Keyphrases
Heavily Pretreated Patients
100%
Neuroendocrine Carcinoma
100%
Topotecan
100%
Advanced Stage
100%
Monotherapy
100%
Etoposide
60%
Platin
40%
Hematotoxicity
40%
Antitumor Activity
20%
Chemotherapy
20%
Chemotherapy Regimen
20%
Previously Treated Patients
20%
Ki-67
20%
Retrospective Analysis
20%
Highly Aggressive
20%
Second-line Treatment
20%
Treatment-related Mortality
20%
Thrombocytopenia
20%
Carboplatin
20%
Aggressive Tumor
20%
Leukopenia
20%
Poor Prognosis
20%
1-year Survival
20%
Female-to-male
20%
Stable Disease
20%
Median Progression-free Survival
20%
Demographic Characteristics
20%
Clinical Features
20%
Pathological Features
20%
CT Examination
20%
Small Cell Lung Cancer
20%
Advanced Disease
20%
Metastasizing
20%
Median Overall Survival
20%
Ki-67 Index
20%
Pharmacology, Toxicology and Pharmaceutical Science
Neuroendocrine Carcinoma
100%
Topotecan
100%
Monotherapy
100%
Etoposide
60%
Diseases
40%
Neoplasm
40%
Chemotherapy
40%
Thrombocytopenia
20%
Small Cell Lung Cancer
20%
Progression Free Survival
20%
Patient History of Chemotherapy
20%
Leukopenia
20%
Overall Survival
20%
Carboplatin
20%
Medicine and Dentistry
Monotherapy
100%
Topotecan
100%
Etoposide
60%
Diseases
40%
Neoplasm
20%
Thrombocytopenia
20%
Antineoplastic Activity
20%
Chemotherapy
20%
Leukopenia
20%
Small Cell Lung Cancer
20%
Overall Survival
20%
Progression Free Survival
20%
Carboplatin
20%
Patient History of Chemotherapy
20%